The Philadelphia spinout is trying to stop acute lung injury before oxidative damage snowballs. Its unusually small peptide has survived mice, pigs and a $25 million financing - but the decisive human test still lies ahead.
After spinning off toothpaste and painkillers, GSK placed a sharper bet on the immune system. Its next chapter is being written in vaccine vials, long-acting HIV medicine and a newly enlarged cancer pipeline.